BG Medicine, Inc. Welcomes Presentation of Clinical Data on Galectin-3 Testing at the American Heart Association 2014 Scientific Sessions Conference
November 20, 2014 08:30 ET
|
BG Medicine, Inc.
WALTHAM, Mass., Nov. 20, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, announced today that 17 abstracts reporting independent research that...
BG Medicine Reports Third Quarter 2014 Financial Results
November 13, 2014 06:30 ET
|
BG Medicine, Inc.
Net Loss Reduced by 35% and Operating Cash Burn Cut by 48% From Third Quarter 2013
Company Retains Investment Bank to Explore Strategic Alternatives
WALTHAM, Mass., Nov. 13, 2014 (GLOBE...
BG Medicine Announces Q3 2014 Financial Results Release Date and Conference Call Information
November 07, 2014 10:45 ET
|
BG Medicine, Inc.
WALTHAM, Mass., Nov. 7, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) today announced that the company will host a conference call and webcast on Thursday, November 13, 2014 at 8:30 a.m....
BG Medicine Reports Second Quarter 2014 Financial Results
August 14, 2014 08:00 ET
|
BG Medicine, Inc.
WALTHAM, Mass., Aug. 14, 2014 (GLOBE NEWSWIRE) -- BGMedicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3®Test, today reported financial results for the second quarter 2014.
Second...
BG Medicine Announces Q2 2014 Financial Results Release Date and Conference Call Information
August 07, 2014 20:00 ET
|
BG Medicine, Inc.
WALTHAM, Mass., Aug. 7, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) today announced that the company will host a conference call and webcast on Thursday, August 14, 2014 at 8:30 a.m....
BG Medicine Reports First Quarter 2014 Financial Results
May 14, 2014 07:30 ET
|
BG Medicine, Inc.
Net Loss Reduced by 60% and Operating Cash Burn Cut by 44% From First Quarter 2013
Continued Progress Made Toward Delivering on Critical Catalysts for Growth
WALTHAM, Mass., May 14, 2014 (GLOBE...
BG Medicine Announces Q1 2014 Financial Results Release Date and Conference Call Information
May 07, 2014 16:30 ET
|
BG Medicine, Inc.
WALTHAM, Mass., May 7, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) today announced that the company will host a conference call and webcast on Wednesday, May 14, 2014 at 8:30 a.m. Eastern...
BG Medicine, Inc. Prices $10.0 Million Public Offering of Common Stock
April 03, 2014 09:15 ET
|
BG Medicine, Inc.
WALTHAM, Mass., April 3, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, today announced the pricing of the sale of 6,452,000 shares of its...
BG Medicine, Inc. Announces Proposed Public Offering of Common Stock
April 02, 2014 16:05 ET
|
BG Medicine, Inc.
WALTHAM, Mass., April 2, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, today announced that it intends to offer and sell shares of its...
Publication Reports Clinical Utility of BGM Galectin-3(R) Test for Prediction of Near-Term Rehospitalization in Patients With Heart Failure
March 25, 2014 08:30 ET
|
BG Medicine, Inc.
WALTHAM, Mass., March 25, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today the publication of results, in the American Heart Journal, of an analysis of aggregated data from...